Background {#Sec1}
==========

Sepsis is a series of life-threatening organ dysfunction events initiated by dysregulated host response to infection \[[@CR1]\]. Disseminated intravascular coagulation (DIC) is a major cause of organ dysfunction in sepsis. It is significantly closely related to mortality and difficult to be recognized before coagulation collapsing \[[@CR2], [@CR3]\]. Recently, multiple studies have confirmed that early diagnosis and intervention of DIC is crucial to disease prognosis \[[@CR4]--[@CR9]\], which highlighted the importance of identifying sepsis-induced coagulopathy (SIC) before it is too late.

MicroRNA (miRNA) is a group of endogenous noncoding small RNAs. They are highly conserved and function as posttranscriptional regulators of gene expression \[[@CR10]\]. It has been reported that levels of miRNAs are stable across the human circulatory system \[[@CR11], [@CR12]\]. MiRNAs have been studied widely as biomarkers for several diseases. MiR-146a, miR-150, miR-4772-5p, miR-15a, miR-223, and miR-499-5p are potential biomarkers for sepsis in human serum/plasma, and down-regulation of miR-574-5p has been shown to be associated with higher risk of mortality \[[@CR13]--[@CR18]\]. However, there has been little study of miRNAs for SIC, according to Wang et al. Some miRNAs have been found to be related to sepsis prognosis. Among these, serum miR-122 was found to be related to coagulation disorder in sepsis patients. Thus, studies on miRNAs in association with SIC are sorely needed.

Lipocalin-2, also called neutrophil gelatinase-associated lipocalin (NGAL), is a 25 kD protein secreted by human neutrophils. Lipocalin-2 is widely used as an index in clinical settings. It can be detected in serum and plasma samples easily and quickly in many inflammatory and metabolic disorders. Its relationship with sepsis has been studied extensively. It has been used as a biomarker for sepsis-associated acute kidney injury and severe sepsis prognosis \[[@CR19]\]. One recent study revealed its regulatory role in gut-origin sepsis \[[@CR20]\]. Another study indicated that plasma lipocalin-2 levels are elevated in DIC patients and related to disease prognosis \[[@CR21]\]. Though the relationship of lipocalin-2 with sepsis and DIC has been studied, no study has yet evaluated its relationship with SIC.

In this study, we sequenced plasma microRNA in sepsis-alone and SIC patients. Four microRNAs were found to be differently expressed including hsa-mir-92a-3p. In the subsequent PCR validation, we observed the hsa-mir-92a-3p expression level was consistent with sequencing results and was associated with plasma lipocalin-2 levels. We then explored the potential of hsa-mir-92a and lipocalin-2 as disease-specific markers.

Methods {#Sec2}
=======

Study design and patient characteristics {#Sec3}
----------------------------------------

Patients were diagnosed with sepsis according to "The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)" \[[@CR1]\]. Exclusion criteria were as follows: ① younger than 18 years old, ② immunocompromised status, ③ pregnancy, ④ malignancy, ⑤ massive transfusion within 24 h of sample collection.

A total of 116 patients (49 SIC and 67 sepsis-alone) were divided into two groups: SIC group and sepsis-alone (SA) group. SIC was defined as proposed by Iba et al. in 2017 \[[@CR22]\]: SIC scores no less than 4 points with total score of prothrombin time and coagulation exceeding 2 points. The SIC score system (Table [1](#Tab1){ref-type="table"}) consisted of three parts: Prothrombin time, which was assessed using PT-INR value; coagulation, assessed by platelet count; and total SOFA, calculated using 4 items (respiratory SOFA, cardiovascular SOFA, hepatic SOFA, and renal SOFA). The SIC score system was proved to be closely correlated with mortality rate. It took the SOFA score into consideration, which was tailored for sepsis-associated coagulopathy \[[@CR22]--[@CR24]\]. Table 1Score system for sepsis-induced coagulopathyCategoryParameter012Prothrombin timePT-INR≤1.2\> 1.2\> 1.4CoagulationPlatelet count (× 10^9^/L)≥150\< 150\< 100Total SOFASOFA four items01≥2*SOFA* Sequencing Organ Failure Assessment

Blood sample and plasma MiRNA isolation {#Sec4}
---------------------------------------

Blood samples were collected from all patients within 24 h of admission to the intensive care unit (ICU) and centrifuged at 3000 rpm for 15 min at room temperature. The supernatant was transferred to Eppendorf tubes and stored at − 80 °C until miRNA extraction. Total plasma miRNA was isolated using a serum/plasma miRNA isolation and extraction kit (Tiangen, Beijing, China) according to the manufacturer's instructions.

Hiseq sequencing and target MiRNA selection {#Sec5}
-------------------------------------------

The plasma samples of 15 SIC patients and 15 SA patients were pooled in two separate groups. Total miRNA were isolated using miRcute miRNA extraction and isolation kit (Tiangen, Beijing, China); gene sequencing was completed by the Beijing Genomics Institute (BGI, Beijing, China).

MiRNAs selected for further validating all met the following two criteria (1) over 20 read numbers; (2) log2Ratio ≥ 2 \[[@CR25], [@CR26]\].

Target MiRNA validation via qRT-PCR {#Sec6}
-----------------------------------

CDNA was synthesized using a miRcute Enhanced miRNA cDNA First-line Synthesis Kit (kr211) and real-time qPCR was performed with a SYBR Green miRNA assay (Tiangen, Beijing, China). Briefly, 8 μl of isolated miRNA was added to a 20 μl system, 42 °C for 60 min followed by 95 °C 3 min for reverse transcription. Two μl of cDNA was added to a 20-μl system tested with ABI 7500 Real-time PCR System in duplication. The program was set according to the manufacture's instruction.

Plasma Lipocalin-2 assessment {#Sec7}
-----------------------------

Lipocalin-2 levels were measured using an enzyme-linked immunosorbent assay (ELISA) kit (Life Technologies, CA, US) with a range of 7.81 to 500 pg/ml. Concentration was determined from standard curves. ELISA was performed in duplicate according to the manufacturer's instructions.

Statistical analysis {#Sec8}
--------------------

Expression levels of selected miRNAs detected by qRT-PCR are here presented with raw Ct values. Results for normally distributed continuous variables were given as means±standard errors and compared between groups using Student's *t* tests. Results for non-normally distributed continuous variables are summarized as medians (interquartile ranges) and compared using the Mann-Whitney U tests. Pearson's analysis was used to evaluate the relationships between pairs of variables. Statistical significance was set at *P* \< 0.05. SPSS 20.0 software was used for all statistical analyses.

A binary logistic regression model was generated after the following hypothesis was tested: ① There is a linear relationship between the continuous independent variable and the logit conversion value of the dependent variable; ② There is no multicollinearity between independent variables; ③ There are no obvious outliers, leverage points, or strong influence points. The variables that showed statistically significant differences in univariate analysis were entered into the binary logistic regression model. Variables were excluded for existence of multicollinearity between independent variables. Finally, six variables were taken into the final analysis as shown in the results.

Results {#Sec9}
=======

Patients {#Sec10}
--------

A total of 116 sepsis patients were included between Nov 2014 and Aug 2017 from emergency intensive care units, respiratory intensive care units, and surgery intensive care units of Beijing Chao-Yang Hospital. Eighty-six patients were included for the validation set and were divided into SIC group (*n* = 34) and SA group (*n* = 52). Patients' clinical characteristics are presented in Table [2](#Tab2){ref-type="table"}. Patients from the two groups were matched by sex (*P* = 0.983), age (*P* = 0.316) and disease severity measured by Acute Physiology and Chronic Health Evaluation (APACHE) II scores (*P* = 0.635). Sources of infection causing sepsis included pulmonary infection, biliary and pancreatic infection, peritonitis, urinary infection, and cerebral infection. There were significantly more cases of pulmonary infection (*P* \< 0.001) and peritonitis (*P* \< 0.001) in the SIC group than in the SA group. Patients were matched for other causes: biliary system and pancreatic infection (*P* = 0.276), urinary infection (*P* = 0.380), and cerebral infection (*P* = 1.000). Most global coagulation tests differed significantly between the two groups except D-dimer (*P* = 0.097) and thrombin time (TT) (*P* = 0.101). There was no difference between the two groups with respect to creatinine (*P* = 0.575) or blood urea nitrogen (BUN) (*P* = 0.299) levels. Table 2Patients' clinical characteristics for validation set (*n* = 86)VariablesSepsis-induced coagulopathy (*n* = 34)Sepsis alone (*n* = 52)*P*-valueSex, F/M61.90%62.50%*P* = 0.983^a^Age, years59.56 ± 17.13163.48 ± 17.927*P* = 0.316^b^Source of infection% Pulmonary58.00% (29)42.00% (21)*P* \< 0.001^a^ Biliary system and pancreatic45.50% (5)54.50% (6)*P* = 0.276^a^ Peritonitis78.90% (15)21.10% (4)*P* \< 0.001^a^ Urinary system60.00% (3)40.00% (2)*P* = 0.380^a^ Cerebral0% (0)100% (1)*P* = 1.000^a^SOFA scores6.68 ± 3.676.04 ± 3.16*P* = 0.393^b^APACHE II scores17.35 ± 7.8816.60 ± 6.73*P* = 0.635^b^28-day mortality%67.7% (21)32.3% (10)*P* \< 0.001^a^PLT (×10\^9/L)108.03 ± 91.99211.10 ± 96.93*P* \< 0.001^b^D-dimer (mg/dL)7.12 (3.00, 18.24)4.60 (2.38, 8.64)*P* \< 0.001^c^APTT (s)44.80 (38.10, 61.10)35.75 (31.70, 43.23)*P* \< .001^c^PT (s)14.90 (13.48, 17.33)12.75 (11.53, 13.88)*P* \< 0.001^c^PA%66.53 ± 17.8981.10 ± 11.98*P* \< 0.001^c^INR1.26 (1.16, 1.47)1.11 (1.03, 1.18)*P* \< 0.001^c^Fbg (mg/dL)275.13 ± 136.45421.50 ± 173.30*P* \< 0.001^b^TT (s)20.00 (18.28, 24.88)19.10 (17.98, 20.70)*P* = 0.055^c^Cr (mmol/L)75.65 (52.90, 137.20)74.25 (53.80, 127.65)*P* = 0.575^c^BUN (mmol/L)10.12 (5.78, 14.07)8.54 (5.06, 12.78)*P* = 0.299^ca^χ2 test, ^b^Student's t test, ^c^Mann-Whitney U test, *SOFA* Sequential organ failure assessment, *APACHE II* Acute physiology and chronic health evaluation, *PLT* Platelet, *APTT* activated partial thromboplastin time, *PT* Prothrombin time, *PA* Prothrombin activity, *INR* International normalized ratio, *Fbg* Fibrinogen, *TT* Thrombin Time, *Cr* Creatine, *BUN* Blood urea nitrogen

Another 30 patients (15 SIC patients and 15 SA patients) were included for gene sequencing, demographic variables were presented in Table [3](#Tab3){ref-type="table"}. Table 3Patients' clinical characteristics for gene sequencing (*n* = 30)VariablesSepsis-induced coagulopathy (*n* = 15)Sepsis alone (*n* = 15)*P*-valueSex, F/M4/118/7*P* = 0.136^a^Age, years62.60 ± 13.9165.13 ± 20.40*P* = 0.694^b^Cause of sepsis% Pulmonary infection75% (9)25% (3)*P* = 0.025^a^ Biliary system and pancreatic20% (1)80% (4)*P* = 0.330^a^ Peritonitis40% (4)60% (6)*P* = 0.439^a^ Urinary system50% (1)50% (1)*P* = 1.000^a^ Cerebral0% (0)100% (1)*P* = 1.000^a^SOFA scores9.00 ± 4.336.21 ± 3.39*P* = 0.060^b^APACHE II scores20.20 ± 8.1915.59 ± 7.77*P* = 0.125^b^PLT (×10\^9/L)131.20 ± 87.78156.87 ± 76.27*P* = 0.400^b^D-dimer (mg/dL)13.94 ± 12.415.72 ± 5.49*P* = 0.026^b^APTT (s)50.80 (39.70, 60.70)34.90 (33.40, 53.20)*P* = 0.062^c^PT (s)17.00 (14.20, 20.10)12.90 (12.50, 18.00)*P* = 0.022^c^PA%62.15 ± 19.4570.51 ± 14.57*P* = 0.193^b^INR1.51 ± 0.541.30 ± 0.29*P* = 0.197^b^Fbg (mg/dL)294.60 (140.60, 340.80)310.30 (254.50, 533.40)*P* = 0.262^c^TT (s)21.50 (19.20, 114.45)23.00 (18.70, 282.90)*P* = 0.787^c^Cr (mmol/L)137.40 (74.05, 232.75)129.56 (77.80, 301.15)*P* = 0.967^c^BUN (mmol/L)11.32 ± 6.4911.45 ± 6.38*P* = 0.959^ba^χ2 test, ^b^Student's t test, ^c^Mann-Whitney U test, *SOFA* Sequential organ failure assessment, *APACHE II* Acute physiology and chronic health evaluation, *PLT* Platelet, *APTT* Activated partial thromboplastin time, *PT* Prothrombin time, *PA* Prothrombin activity, *INR* International normalized ratio, *Fbg* Fibrinogen, *TT* Thrombin Time, *Cr* Creatine, *BUN* Blood urea nitrogen

Hsa-mir-92a-3p expressed differently between SIC group and SA group {#Sec11}
-------------------------------------------------------------------

According to the results of gene sequencing, we chose hsa-miR-143-3p, hsa-miR-185-3p, hsa-miR-92a-3p, and hsa-miR-30c-3p for further measurement; mean reads and log2 ratio of four miRNAs are shown in Table [4](#Tab4){ref-type="table"}. The Student's *t* test revealed significance only for level of hsa-mir-92a-3p: SIC group vs. SA group (17.86 ± 1.44 vs. 18.66 ± 1.21, *P* = 0.007) (Fig. [1](#Fig1){ref-type="fig"}). Table 4Differently expressed miRNAs in miRNAs sequencingmiR_nameSA ReadsSIC Readslog2Ratio*P*-valueq-valuehsa-miR-92a-3p91849651−4.9600hsa-miR-143-3p59599641−4.3300hsa-miR-30c-5p645335−5.9700hsa-miR-185-5p6632718−2.9900*miR* microRNA, *SA* Sepsis Along, *SIC* Sepsis Induced Coagulopathy Fig. 1Comparisons of the levels of four miRNAs between SIC group (*n* = 34) and SA group (*n* = 52). **a**. Comparison of plasma hsa-mir-92a-3p between SIC and SA group, **b**. Comparison of plasma hsa-mir-143-3p between SIC and SA group, **c**. Comparison of plasma hsa-mir-185-3p between SIC and SA group, **d**. Comparison of plasma hsa-mir-30c-3p between SIC and SA group, \* by Student's t test, SIC = Sepsis-Induced Coagulopathy, SA = Sepsis-Along

Plasma Hsa-mir-92a level related to global coagulation index {#Sec12}
------------------------------------------------------------

We recorded patients' global coagulation tests results including D-dimer, activated partial thromboplastin time (APTT), prothrombin activity (PA), fibrinogen (FBG), and thrombin time (TT). Statistical analysis revealed a strong relationship between hsa-mir-92a and PA (Pearson's correlation coefficients = 0.266, *P* = 0.013) and hsa-mir-92a and APTT (Pearson's correlation coefficients = − 0.325, *P* = 0.002).

Plasma Hsa-miR-92a level related to plasma Lipocalin-2 level {#Sec13}
------------------------------------------------------------

We measured plasma lipocalin-2 levels and found plasma lipocalin-2 expression to differ between the SIC and SA groups (246.05 ± 169.95 pg/ml vs. 168.84 ± 105.30 pg/ml, *P* = 0.011) (Fig. [2](#Fig2){ref-type="fig"}) and to be related to plasma hsa-miR-92a level (Pearson's correlation coefficients = − 0.282, *P* = 0.009). Fig. 2Comparisons of the levels of lipocalin-2 between SIC group (*n* = 34) and SA group (*n* = 52). \* Student's t test, SIC = Sepsis-Induced Coagulopathy, SA = Sepsis-Along

Diagnostic values of Hsa-miR-92a and Lipocalin-2 {#Sec14}
------------------------------------------------

Results showed hsa-miR-92a and lipocalin-2 could be used to distinguish sepsis-induced coagulopathy from sepsis-alone patients. To compare the diagnostic values of these two biomarkers, receiver operating characteristic (ROC) curves were generated and area under the curve (AUC) was calculated. Hsa-miR-92a had an AUC of 0.660 (*P* = 0.011, 95% CI, 0.537, 0.782) in predicting the absence of SIC whereas lipocalin-2 had an AUC of 0.619 (*P* = 0.084, 95% CI, 0.485, 0.752) in predicting SIC (Fig. [3](#Fig3){ref-type="fig"}, Fig. [4](#Fig4){ref-type="fig"}). When the cutoff point was set at 261.01 pg/mL, lipocalin-2 had the highest specificity of 84.6% (Table [5](#Tab5){ref-type="table"}). Fig. 3Receiver operating characteristic curves of hsa-mir-92a-3p for SIC group (*n* = 34) and SA group (*n* = 52). AUC = Area Under Curve Fig. 4Receiver operating characteristic curves of lipocalin-2 for SIC group (*n* = 34) and SA group (*n* = 52). AUC = Area Under Curve Table 5Diagnostic values of has-miR-92a and lipocalin-2BiomarkerAUC (95% CI)Cutoff pointSensitivity%Specificity%Hsa-miR-92a0.660 (0.537, 0.782)17.1841.20%58.80%lipocalin-20.619 (0.485, 0.752)261.01 pg/mL50%84.60%Hsa-miR-92a + lipocalin-20.687 (0.578, 0.782)0.4613952.94%84.62%*AUC* Area under curve

We then generated the ROC for a combination of hsa-mir-92a and lipocalin-2 (Fig. [5](#Fig5){ref-type="fig"}). The AUC for hsa-mir-92a + lipocalin-2 was 0.687 (*P* = 0.003, 95% CI, 0.578, 0.782). Fig. 5Receiver operating characteristic curves of hsa-mir-92a-3p and lipocalin-2 for SIC group (*n* = 34) and SA group (*n* = 52). AUC = Area Under Curve

Risk factors for Sepsis-induced coagulopathy {#Sec15}
--------------------------------------------

As shown, hsa-mir-92a was differently expressed between SIC and SA groups. Because we hypothesized sepsis accompanied by coagulation disorder indicated more disease severity, APACHEII score was also taken into analysis. The analysis of basic information indicated a difference in the number of patients with each specific source of pulmonary infection and peritonitis; these variables were taken into a binary logistic regression model.

Finally, we used a binary logistic regression model to assess the influence of the plasma level of hsa-mir-92a, APACHEII score, pulmonary infection and peritonitis, D-dimer level, and fibrinogen for SIC. There were linear relationships between dependent variables and covariates and one case with a ZResid of 3.386 times the standard deviation. These were analyzed further. The model was significant, 0.531 for Hosmer and Lemeshow goodness of fit test. Among the six independent variables included in the model, mir-92a and fibrinogen had statistical significance. For each unit of increase in plasma mir-92a level, the risk of SIC decreased by 32.4%, and for each unit of increase in plasma fibrinogen level, the risk of SIC decreased by 0.7%. The result and odds ratio with its 95% CI are given in Table [6](#Tab6){ref-type="table"}. Table 6Risk factors for sepsis-induced coagulopathy95% CIVariablesDF*P* valueORLowerUpperHsa-mir-92a10.0350.6580.4460.970Fibrinogen10.0010.9930.9890.997D-dimer10.0931.0500.9921.111APACHEII10.9371.0030.9321.080Pulmonary Infection10.4020.6000.1821.979Peritonitis10.8570.8530.1504.856Constant10.01910,504.227The binary logistic model included six variables: plasma level of hsa-mir-92a, Fibrinogen, D-dimer, APACHE II score, pulmonary infection and Peritonitis. *APACHEII* Acute physiology and chronic health evaluation, *DF* Degree of freedom, *OR* Odds ratio, *CI* Confident interval

Discussion {#Sec16}
==========

Sepsis is a life-threatening situation. It is often accompanied by coagulation disorder, and it can leave clinicians stymied in the attempt to identify the optimum treatment. It would be useful to find new biomarkers and therapeutic targets. In this study, we found novel biomarkers for SIC. After Hiseq sequencing, we located four differently expressed miRNAs in human plasma and validated our findings in a larger sample. Plasma lipocalin-2 was measured as well. We found significant differences in both hsa-mir-92a and lipocalin-2 levels between SIC and SA groups. There were higher plasma levels of hsa-mir-92a in the SA group than in the SIC group, but the higher plasma lipocalin-2 level indicated a greater possibility of SIC. We also found a strong relationship between hsa-mir-92a and prothrombin activity, activated partial thromboplastin time, and lipocalin-2.

MiR-92a has been widely studied in tumorigenesis and metastasis of several different kinds of tumors. MiR-92a is significantly up-regulated in colon rectal cancer tissues and correlated with metastases and poor prognosis \[[@CR27]\]. It also participates in gene regulation processes in other kinds of tumors including non-Hodgkin's lymphoma, acute lymphoid leukemia, multiple myeloma, breast cancer, lung cancers, hepatocellular carcinoma, and esophageal squamous cell carcinoma, acting as both tumor suppressor and oncogene \[[@CR28]--[@CR34]\].

Mir-92a was found to be involved in angiogenesis and endothelial cell function \[[@CR35]\]. Bonauer et al. found that human endothelial cells (ECs) express the miR-17--92 cluster, particularly its member miR-92a. Forced overexpression of miR-92a in human ECs impairs EC function, and inhibition of miR-92a can enhance vessel growth. One in vivo study with a mouse hind limb ischemia model revealed that the number of capillaries and smooth muscle actin-positive arterioles increases after antagomir-92a treatment. In searching for possible pathways and putative target genes for mir-92a, the mRNAs for integrin subunits ɑ5 (ITGA5) and ɑv, sphingosine-1-phosphate receptor 1 (S1PR1), and mitogen-activated kinase 4 (MKK4) were found to show less expression in response to miR-92a overexpression. Further study on downstream pathways by silencing ITGA5 expression, resembling the effect of miR-92a on mRNA expression, revealed the expression levels of a second group of genes might be secondarily regulated as a consequence of ITGA5 downregulation. These genes include CD31, whose product is a platelet/endothelial cell adhesion molecule, and VWF, whose product is a Von Willebrand factor. The mir-92a-ITGA5-VWF axis could lead to low expression of Von Willebrand factor and cause instability of FVIII, finally resulting in prolonged APTT.

Lipocalin-2 has been studied as a clinical biomarker for DIC in its different forms: plasma free and total lipocalin-2 levels were significantly higher in patients with overt-DIC than in those without overt-DIC. The free lipocalin-2 level also showed a significant prognostic value in DIC \[[@CR36]\]. In the search for a possible regulatory mechanism for mir-92a and lipocalin-2, studies have focused on apoptotic cell-derived sphingosine-1-phosphate (S1P), which induces the production and release of lipocalin-2 by human macrophages through the S1P-S1PR1-signal transducer and activator of transcription 3 (STAT3)-lipocalin-2 axis in lymphangiogenesis and tumor metastasis \[[@CR37], [@CR38]\]. Mir-92a has been confirmed to play a role in the regulation of S1PR1 \[[@CR35]\]. Increased mir-92a could lead to downregulation of S1PR1 and upregulation of lipocalin-2. However, this model still needs confirmation.

There are limitations to this study. First, without a basal level of miRNA expression in healthy controls, we could not determine whether the differently expressed miRNAs also differed between the SIC group and healthy controls in the same way. Second, because no optimum normalizer exists for such critical conditions as sepsis and severe infection \[[@CR39]\], raw Ct value was taken into further analysis, which can cause bias due to individual difference and different sample degeneration states.

Conclusions {#Sec17}
===========

In this work, we evaluated differently expressed miRNAs between SA and SIC patients. After validation, plasma hsa-mir-92a was confirmed as a diagnostic biomarker for sepsis-induced coagulopathy and related to global coagulation index and plasma lipocalin-2 level. Further study is needed to confirm the regulatory role of hsa-mir-92a-3p in coagulation disorders and assess therapeutic potency.
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